Suppr超能文献

糖蛋白41胞外域的结构域交换构建体是HIV感染的有效抑制剂。

Swapped-domain constructs of the glycoprotein-41 ectodomain are potent inhibitors of HIV infection.

作者信息

Chu Shidong, Kaur Hardeep, Nemati Ariana, Walsh Joseph D, Partida Vivian, Zhang Shao-Qing, Gochin Miriam

机构信息

†Department of Basic Sciences, Touro University-California, Vallejo, California 94592, United States.

‡Department of Pharmaceutical Chemistry, University of California, San Francisco, California 94143, United States.

出版信息

ACS Chem Biol. 2015 May 15;10(5):1247-57. doi: 10.1021/cb501021j. Epub 2015 Feb 17.

Abstract

The conformational rearrangement of N- and C-heptad repeats (NHR, CHR) of the HIV-1 glycoprotein-41 (gp41) ectodomain into a trimer of hairpins triggers virus-cell fusion by bringing together membrane-spanning N- and C-terminal domains. Peptides derived from the NHR and CHR inhibit fusion by targeting a prehairpin intermediate state of gp41. Typically, peptides derived from the CHR are low nanomolar inhibitors, whereas peptides derived from the NHR are low micromolar inhibitors. Here, we describe the inhibitory activity of swapped-domain gp41 mimics of the form CHR-loop-NHR, which were designed to form reverse hairpin trimers exposing NHR grooves. We observed low nanomolar inhibition of HIV fusion in constructs that possessed the following properties: an extended NHR C-terminus, an exposed conserved hydrophobic pocket on the NHR, high helical content, and trimer stability. Low nanomolar activity was independent of CHR length. CD studies in membrane mimetic dodecylphosphocholine micelles suggested that bioactivity could be related to the ability of the inhibitors to interact with a membrane-associated prehairpin intermediate. The swapped-domain design resolves the problem of unstable and weakly active NHR peptides and suggests a different mechanism of action from that of CHR peptides in inhibition of HIV-1 fusion.

摘要

HIV-1糖蛋白41(gp41)胞外域的N端和C端七肽重复序列(NHR、CHR)构象重排形成发夹三聚体,通过将跨膜的N端和C端结构域聚集在一起引发病毒-细胞融合。源自NHR和CHR的肽通过靶向gp41的前发夹中间状态来抑制融合。通常,源自CHR的肽是低纳摩尔抑制剂,而源自NHR的肽是低微摩尔抑制剂。在此,我们描述了CHR-环-NHR形式的结构域交换型gp41模拟物的抑制活性,其设计目的是形成暴露NHR凹槽的反向发夹三聚体。我们在具有以下特性的构建体中观察到对HIV融合的低纳摩尔抑制:NHR C端延长、NHR上暴露的保守疏水口袋、高螺旋含量和三聚体稳定性。低纳摩尔活性与CHR长度无关。在模拟膜的十二烷基磷酸胆碱胶束中的圆二色性研究表明,生物活性可能与抑制剂与膜相关前发夹中间体相互作用的能力有关。结构域交换设计解决了NHR肽不稳定和活性弱的问题,并提示了一种与CHR肽抑制HIV-1融合不同的作用机制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c91b/4562464/429d2c82f1ff/nihms-716824-f0001.jpg

相似文献

5
Peptide and non-peptide HIV fusion inhibitors.肽类和非肽类HIV融合抑制剂。
Curr Pharm Des. 2002;8(8):563-80. doi: 10.2174/1381612024607180.

本文引用的文献

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验